Product
Setanaxib
3 clinical trials
4 indications
Indication
Primary Biliary CholangitisIndication
FibrosisIndication
Squamous Cell Carcinoma of Head and NeckIndication
Alport SyndromeClinical trial
TRANSFORM: A 24-week, Randomized, Placebo-controlled, Double-blind, Phase 2b Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Elevated Liver StiffnessStatus: Active (not recruiting), Estimated PCD: 2024-07-06
Clinical trial
A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Setanaxib, When Administered With Pembrolizumab, in Patients With Recurrent or Metastatic SCCHNStatus: Active (not recruiting), Estimated PCD: 2024-02-18
Clinical trial
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the NOX1/4 Inhibitor Setanaxib in Patients With Alport SyndromeStatus: Recruiting, Estimated PCD: 2025-01-27